Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo StudyGlobeNewsWire · Oct 15, 2026
Edesa Biotech Announces Pricing of $25.0 Million Public OfferingGlobeNewsWire · Aug 19, 2026
Edesa Biotech Announces Proposed Public OfferingGlobeNewsWire · Aug 19, 2026
Edesa Biotech Reports Fiscal 3rd Quarter 2026 ResultsGlobeNewsWire · Aug 13, 2026Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.44 | -$0.60 | Miss |
| May 14, 2026 | -$0.24 | -$0.49 | Miss |
| Feb 13, 2026 | -$0.28 | -$0.28 | Beat |
| Dec 12, 2025 | -$0.27 | -$0.32 | Miss |
| Aug 8, 2025 | -$0.26 | -$0.25 | Beat |
| May 14, 2025 | -$0.30 | -$0.30 | Beat |